[Relevance of HIV resistance testing for treatment decisions].

Orna Mor*, Zehava Grossman, Boaz Avidor, Dan Turner

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Resistance testing is part of the routine checkup for HIV carriers in Israel and in most of the developed world. Viruses with mutations which confer resistance to antiretroviral therapy in treated patients and in new HIV carriers are identified. The results of these tests form the basis for updating the HIV treatment guidelines and contribute to the epidemiological and phylogenetic understanding of the HIV epidemic. The viral reverse transcriptase and protease are the targets for most of the antiretroviral drugs in use today and are included in the standard resistance testing. Recently, genotypic examination of the integrase and tropism test to verify use of the HIV CCR5 co-receptor have been introduced to better support treatment decisions and to enable effective use of all available drug combinations. New and more sensitive molecular tests, such as ultra-deep sequencing, are expected to broaden our knowledge of rare mutations not detected by the currently used methodologies. Consequently, we will be able to improve treatment strategy and life quality and increase Life expectancy of HIV carriers.

Original languageEnglish
Pages (from-to)230-234, 245-246
JournalUnknown Journal
Issue number4
StatePublished - Apr 2013


Dive into the research topics of '[Relevance of HIV resistance testing for treatment decisions].'. Together they form a unique fingerprint.

Cite this